NCT06105619 2026-01-20
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Beijing Pearl Biotechnology Limited Liability Company
Phase 2/3 Active not recruiting
Clinical Trials
10 trialsNCT07349693 2026-01-20
Cerebraca-02/3
Everfront Biotech Co., Ltd.
Phase 2/3 Not yet recruiting
NCT04250922 2025-11-20
CLINGLIO
Laminar Pharmaceuticals
Phase 2/3 Active not recruiting
NCT05130866 2025-10-07
POPLAR-NF2
Recursion Pharmaceuticals Inc.
Phase 2/3 Terminated
NCT03653546 2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3 Completed
NCT03579602 2024-06-27
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery
Blaze Bioscience Inc.
Phase 2/3 Completed
NCT03275402 2024-02-13
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Y-mAbs Therapeutics
Phase 2/3 Terminated
NCT03008148 2021-05-11
Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
Johnpro Biotech, Inc.
Phase 2/3 Unknown
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated
NCT00427583 2012-08-07
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Novartis
Phase 2/3 Terminated